BioVectra
BioVectra is a Canadian full-service CDMO providing clinical-to-commercial scale contract manufacturing of biologics, small molecules, HPAPIs, mRNA/pDNA, and aseptic fill-finish products, serving 18 of the top 20 global pharmaceutical and biotechnology companies from five GMP facilities in Atlantic Canada, now operating within Agilent Advanced Therapeutics.
- Company typePrivate
- Founded1970
- HeadquartersCharlottetown, Canada
- Headcount501–1,000
- GTM typeB2B
- OfferingServices
What BioVectra does
BioVectra is a full-service contract development and manufacturing organization (CDMO) headquartered in Charlottetown, Prince Edward Island, Canada, with operations dating to 1970. The company provides clinical-to-commercial scale manufacturing services to the global pharmaceutical and biotechnology industry, with an enterprise-focused customer base that includes 18 of the top 20 global pharma and biotech companies. BioVectra serves more than 100 active clients across multiple geographies, earning revenue primarily through fee-for-service contract manufacturing agreements that span process development, analytical method development, GMP manufacturing, and fill-finish operations.
BioVectra's technology platform integrates four core manufacturing modalities: microbial fermentation (supporting recombinant proteins, plasmid DNA, and antibody fragments using BSL-1 systems including E. coli and Pichia pastoris), mammalian cell culture, complex synthetic chemistry for small molecule APIs, and aseptic fill-finish with capacity for up to 40,000 filled vials per day. The company also operates specialized HPAPI manufacturing capabilities with OELs down to 20 ng/m³ (SafeBridge Band 3 & 4), and end-to-end mRNA and plasmid DNA production capabilities including LNP formulation, integrated through a 36,000 sq ft mRNA Biomanufacturing Centre. Five GMP-certified facilities across Atlantic Canada anchor these capabilities, supported by strategic partnerships with Revolution Biomanufacturing (mRNA design) and Acuitas Therapeutics (LNP delivery technology).
The business operates on a project-based revenue model with multi-year supply contracts, where pricing is negotiated per project based on molecule complexity, manufacturing scale, and regulatory pathway. Distribution is exclusively through direct enterprise sales with dedicated business development teams engaging top-tier pharma and biotech clients. Following its September 2024 acquisition by Agilent Technologies for $925 million, BioVectra now operates as part of Agilent's Diagnostics and Genomics Group and serves as the foundation of Agilent Advanced Therapeutics, a unified CDMO platform launched in March 2026 that integrates BioVectra's Canadian operations with Agilent's Nucleic Acid Solutions in Colorado.
BioVectra firmographics
Firmographics- Name
- BioVectra
- Legal name
- BIOVECTRA Inc.
- Website
- https://biovectra.com
- Company type
- Private
- Founded year
- 1970
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- BioVectra is a Canadian full-service CDMO providing clinical-to-commercial scale contract manufacturing of biologics, small molecules, HPAPIs, mRNA/pDNA, and aseptic fill-finish products, serving 18 of the top 20 global pharmaceutical and biotechnology companies from five GMP facilities in Atlantic Canada, now operating within Agilent Advanced Therapeutics.
- Ownership category
- akta.pro rank
BioVectra industry classification
Industry- Product category
- Pharmaceutical Contract Manufacturing
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)
- akta.pro secondary industries
- mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC), Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH), Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)
Keywords
Where BioVectra is headquartered
LocationHeadquarters
- HQ city
- Charlottetown
- HQ country
- Canada
- HQ region
- North America
Offices3 records
Markets served
BioVectra business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain
Revenue model
- Contract Manufacturing Services: BioVectra generates revenue primarily through fee-for-service contract manufacturing agreements. Customers engage BioVectra for specific stages of drug development and commercial production, including process development, analytical method development, GMP manufacturing, and fill-finish. Revenue is earned as services are rendered or upon milestone completion under long-term supply contracts. The model is project-based and recurring through multi-year client relationships.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom project-based pricing |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
BioVectra product offering
Product offeringCore offering
BioVectra is a full-service Contract Development and Manufacturing Organization (CDMO) providing clinical-to-commercial scale production of biologics, synthetic small molecules, plasmid DNA/mRNA, lipid nanoparticles (LNP), highly potent APIs (HPAPIs), bioreagents, and aseptic fill-finished drug products. The company operates five GMP manufacturing facilities across Atlantic Canada, leveraging microbial fermentation, mammalian cell culture, synthetic chemistry, and sterile fill-finish capabilities to serve global pharmaceutical and biotechnology clients.
Product overview
BIOVECTRA is a full-service CDMO (Contract Development and Manufacturing Organization) offering clinical-to-commercial scale production across multiple therapeutic modalities. The company operates as a unified platform with core capabilities including Biologics Manufacturing (microbial fermentation, recombinant proteins, pDNA, mRNA), Synthetic Small Molecules (complex chemistry, APIs), Highly Potent APIs (HPAPIs), Fermented Small Molecules, Bioreagents, Fill/Finish Services, and Gene Editing Manufacturing. Under the Agilent Advanced Therapeutics platform, BIOVECTRA provides end-to-end services from discovery through commercial manufacturing, supported by Project Support Services for process engineering, quality, and regulatory expertise. The company maintains 5 GMP facilities across Prince Edward Island and Nova Scotia, Canada, with specialized mRNA biomanufacturing capacity of 160 million doses per year.
Differentiator
Problem solved
Functional benefit
Products and services
- Biologics Manufacturing
Quantifiable outcome
- Serves 18 of the top 20 global pharmaceutical and biotechnology companies
- +2 more outcomes
Companies that use BioVectra
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles1 record
BioVectra technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
BioVectra partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and supporting.
- Revolution BiomanufacturingcoreStrategic partnership enabling integrated mRNA design and GMP production services. The collaboration combines BioVectra's CDMO capabilities with Revolution Biomanufacturing's mRNA platform expertise, providing clients a streamlined path from mRNA design through GMP manufacturing. Announced November 6, 2025.
- Acuitas TherapeuticscoreService agreement providing BioVectra clients access to Acuitas Therapeutics' industry-leading lipid nanoparticle (LNP) delivery system technology. This enables integrated mRNA development and delivery solutions for clients developing mRNA-based therapeutics and vaccines.
- CCRM, Cytiva (Precision Nanosystems), Northern RNA, OmniaBiosupportingBioVectra is part of a Canadian ecosystem of advanced therapy partners including CCRM (cell and gene therapy), Cytiva/Precision Nanosystems (nanotechnology delivery), Northern RNA (RNA manufacturing), and OmniaBio (biologics and cell therapy manufacturing). Together, these organizations offer an integrated Canadian supply chain solution for immunotherapies and lentiviral vector development, reducing the need for Canadian biotech companies to seek manufacturing capabilities outside the country.
Scale indicators6 records
Recent moves10 records
Expansion highlights6 records
BioVectra competitors and assessment
Company assessmentBroad incumbents
- Lonza Group: Global CDMO leader offering microbial and mammalian biologics manufacturing, mRNA services, and fill-finish. Comparable as a full-service CDMO serving top-20 pharma with similar integrated modality breadth, though at significantly larger scale.
- Catalent: Major global CDMO with biologics, fill-finish, and nucleic acid manufacturing capabilities. Comparable in offering CDMO services across biologics modalities and serving large pharma; differs in its broader oral and softgel specialty franchise.
- Fujifilm Diosynth Biotechnologies: Large CDMO offering microbial and mammalian biologics, gene therapy, and vaccines manufacturing. Comparable in integrated biologics CDMO services with microbial fermentation expertise; larger scale and broader global footprint.
- WuXi Biologics: World's largest biologics CDMO with end-to-end microbial and mammalian services, including mRNA. Comparable CDMO offering across biologics modalities and top-20 pharma clients; significant pricing pressure on North American CDMOs.
- Samsung Biologics: Large-scale biologics CDMO with substantial mammalian cell culture capacity. Comparable in serving top-20 pharma with biologics manufacturing, but at much larger scale with different geographic footprint.
Direct peers
- AGC Biologics: Mid-to-large CDMO specializing in microbial and mammalian biologics, gene therapy, and mRNA manufacturing. Directly comparable to BioVectra in microbial fermentation focus and CDMO service model for biologics and nucleic acids.
- Recipharm: European-based CDMO offering biologics, fill-finish, and small molecule API manufacturing. Comparable as a full-service CDMO with similar project-based revenue model serving pharma clients, though with different geographic footprint.
- Rentschler Biopharma: CDMO specializing in microbial and mammalian cell culture-based biopharmaceuticals with aseptic fill-finish. Directly comparable to BioVectra's biologics core, with similar mid-tier scale and European-headquartered operations.
- Eurofins CDMO: European CDMO offering biologics, small molecule API, and HPAPI manufacturing services. Comparable as a mid-tier integrated CDMO with similar modality breadth and project-based revenue model.
- ten23 health: Swiss CDMO specializing in sterile injectable fill-finish and biologics manufacturing for challenging modalities. Comparable in aseptic fill-finish and biologics capabilities, particularly for small-to-mid-sized pharma clients seeking specialized services.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat6 records
Customer concentration
BioVectra social profiles
Digital presenceBioVectra financial estimates
Financial estimateRevenue estimate
Valuation estimate
BioVectra leadership team
Management profileNumber of profiles
Profiles12 records
BioVectra funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BioVectra M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BioVectra
What does BioVectra do?
BioVectra is a full-service Contract Development and Manufacturing Organization (CDMO) providing clinical-to-commercial scale production of biologics, synthetic small molecules, plasmid DNA/mRNA, lipid nanoparticles (LNP), highly potent APIs (HPAPIs), bioreagents, and aseptic fill-finished drug products. The company operates five GMP manufacturing facilities across Atlantic Canada, leveraging microbial fermentation, mammalian cell culture, synthetic chemistry, and sterile fill-finish capabilities to serve global pharmaceutical and biotechnology clients.
Is BioVectra a public or private company?
BioVectra is a private company. It is classified as corporate owned and is currently operating.
When was BioVectra founded?
BioVectra was founded in 1970. It employs 501 to 1,000 people.
Where is BioVectra based?
BioVectra is headquartered in Charlottetown, Canada, in the North America region.
How does BioVectra make money?
One revenue line is on record: contract Manufacturing Services.
Who are BioVectra's main competitors?
Broad incumbents on record are Lonza Group, Catalent, Fujifilm Diosynth Biotechnologies, WuXi Biologics and Samsung Biologics. Direct peers are AGC Biologics, Recipharm, Rentschler Biopharma, Eurofins CDMO and ten23 health.
Does BioVectra have an API?
No public API is recorded for BioVectra.
What industry is BioVectra in?
BioVectra's product category is Pharmaceutical Contract Manufacturing. Its primary akta.pro industry code is HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO, with a secondary code of HLAGAGAC, mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA). Its NAICS code is 325414 and its SIC code is 2836.